21.2 C
New York
Thursday, June 18, 2026

Tag: study

AbolerIS Pharma Presents New Data Supporting CD45RC as a Novel Therapeutic Target and Potential Biomarker in Sjögren’s Disease at EULAR 2026

- Findings demonstrate strong correlation between CD45RC expression and lymphocytic infiltration in salivary glands, supporting its potential as both an early biomarker and therapeutic...

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).

Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032

MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032 (the “Convertible Notes”). The aggregate principal amount of the offering was increased from the previously announced offering size of $400,000,000.

2026 ASCO LBA | Juncell Therapeutics’ GC101 TIL Therapy Achieves Primary Endpoint in the Pivotal Phase II Trial for PD-1 Antibody Failed Advanced Melanoma

SHANGHAI, June 3, 2026 /PRNewswire/ -- On June 1 (Chicago time), in a Late-Breaking Abstract (LBA) oral presentation at the 2026 American Society of Clinical...

Seer Files Definitive Proxy Materials and Mails Letter to Stockholders

Reinforces Seer’s Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity

Thea Serves Its One Billionth Practice Question, Cementing Its Place as a Leader in AI-Powered Active Learning

ARLINGTON, Va., June 3, 2026 /PRNewswire/ -- In an era when millions of students turn to AI to have answers handed to them, Thea has...

Justice Necessary launches HygienePalooza, a statewide tour to bring hygiene essentials to Colorado students

Volunteers will assemble hygiene kits for K–12 school, college and university food pantries across four Colorado cities, addressing a critical gap left by federal...

Booking Health Announces Release of Findings on International Access to Personalized Glioblastoma Treatment in Germany

Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.

Dianetics Volunteers Close Out Mental Health Awareness Month Across Los Angeles

Los Angeles Dianetics volunteers joined a global outreach offering Dianetics and free stress tests to raise awareness and close out Mental Health Awareness

dltHub Named 2026 Snowflake Startup Program Product Partner of the Year

SAN FRANCISCO, June 3, 2026 /PRNewswire/ -- dltHub, the company behind the open-source Python library dlt and the agentic data engineering platform dltHub Pro,...

Globaltech Corp. (OTCQB: GLTK) Update to Shareholders

RENO, Nevada, June 03, 2026 (GLOBE NEWSWIRE) -- Globaltech Corporation (“Globaltech” or the “Company”) (OTCQB: GLTK), a U.S.-based technology holding company, is providing this Update to Shareholders to discuss: (i) how we are managing and operating the Company day to day, (ii) our near-term priorities with a long-term orientation, and (iii) how we responsibly and methodically approach innovation, including AI-enabled products and services.

ProBio and GCP ClinPlus Partner to Accelerate Clinical Trials in China

ProBio and GCP ClinPlus today announced a strategic collaboration designed to accelerate Investigator-Initiated Trials (IITs) in China and provide integrated, end-to-end clinical and development...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

New Anglia University: Is Spending Six Years Abroad Still the Best Route Into Medicine?

New Anglia University examines changing medical education pathways, including international medical education and NHS clinical experience.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStudy